Trial Profile

Phase 1a First-in-Human Study of Safety and Tolerability of ASV AGEN2017 With QS-21 Stimulon Adjuvant as a Single Agent in Subjects With Solid Tumor at Risk of Relapse Undergoing Observation as SOC Following Complete Surgical Resection

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AutoSynVax (Primary) ; QS 21 (Primary)
Indications Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Agenus

01 Dec 2021 Status changed from active, no longer recruiting to completed.
08 Jun 2020 Planned End Date changed from 1 Dec 2020 to 1 Sep 2021.
08 Jun 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Feb 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com